Image Ben Hargreaves Oncology Beyond COVID-19: mRNA vaccines aim to revolutionise cancer c... mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. Market Access Inflation Reduction Act proves positive boost for biosimilar... For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments. R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies. Patients The high cost of inequality: High US healthcare spend falls ... Healthcare in the US is facing a cost crisis and one part of the puzzle could be to address the inequality that persists within the system. Load more results
Oncology Beyond COVID-19: mRNA vaccines aim to revolutionise cancer c... mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment.
Market Access Inflation Reduction Act proves positive boost for biosimilar... For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments.
R&D Weight loss gold rush: Developers vie for next blockbuster t... Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.
Patients The high cost of inequality: High US healthcare spend falls ... Healthcare in the US is facing a cost crisis and one part of the puzzle could be to address the inequality that persists within the system.
News Gilead's twice-yearly HIV PrEP set for wider rollout The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
